31stseagamesvietnam| Financial report express: Haiwang Biotech's full-year net loss in 2023 is 1.690 billion yuan

On April 30th, Haiwang Biology (000078) (000078), an A-share listed company, released its annual report for 2023. Of which, the net loss is 16.31stseagamesvietnam90 billion yuan, an increase of 64 percent over the same period last year.31stseagamesvietnam.56%.

According to the financial diagnosis model of flush (300033), there are more than 1200 financial indicators of its financial data in the current period and in the past 5 years.31stseagamesvietnamAccording to the comprehensive operation and follow-up analysis, the overall financial situation of Haiwang biology in the past five years is lower than the industry average. Specifically, the asset quality, cash flow, debt paying ability is general, and the operating ability is excellent.

The net loss was 1.69 billion yuan, which increased by 64.56% compared with the same period last year.

In terms of revenue and profit, the company's total operating income during the reporting period was 36.419 billion yuan, down 3.74 percent from the same period last year, with a net loss of 1.69 billion yuan, an increase of 64.56 percent over the same period last year, and basic earnings per share of-0.64 yuan.

In terms of assets, during the reporting period, the total assets at the end of the period were 32.305 billion yuan and the accounts receivable were 17.357 billion yuan.31stseagamesvietnamIn terms of cash flow, the net cash flow generated by business activities is-410 million yuan, and the cash received from the sale of goods and services is 38.321 billion yuan.

The financial situation is poor, there are 7 financial risks

According to the relevant financial information released by Haiwang Biology, there are seven financial risks in the company, as follows:

The average rate of return on net assets is-22.15%, and the company's profitability is very weak. The average operating margin is-1.70%, and the company's ability to make money is very weak. The average year-on-year growth rate of performance deduction non-net profit is-687.69%, and the company's growth ability is very weak. The average year-on-year growth rate of net profit is-288.21%, and the growth of the company is very low. Revenue in the growth period fell 18.78% compared with the same period last year, with a higher decline in revenue. The net profit of the growth period decreased by 42.79% compared with the same period last year, and the profit dropped greatly. Deposit and loan double high currency fund is 3.769 billion, short-term loan is 10.778 billion, there is high risk of both deposit and loan.

Overall, the overall financial situation of Haiwang is lower than the industry average, with a current total score of 1.32, ranking low among 31 companies in the pharmaceutical business industry. Specifically, the asset quality, cash flow, debt paying ability is general, and the operating ability is excellent.

The scores of the indicators are as follows:

Index type previous period score ranking asset quality 0.311.6122 general cash flow 1.091.4523 general solvency 2.031.2924 general growth ability 0.470.1631 weaker profitability 0.470.1631 lower operating ability 4.844.037 excellent total score 1.551.3228 lower than industry average

On the large model of financial diagnosis of flush

Flush (300033) Financial diagnosis model calculates the company's financial scores, highlights and risks based on the company's latest and previous financial data and industry conditions, reflecting the company's disclosed financial position, but not a forecast of the future financial position. The financial score range is 0-5. The higher the score, the better the financial situation and the greater the value of the medium-and long-term investment. In the financial highlights and risk reviews, the five-year average of the indicators related to the "average" keyword, and the latest reporting period data without the "average" keyword. All the above information is based on artificial intelligence algorithm, for reference only, does not represent flush financial point of view, investors operate accordingly, at their own risk.

Learn more about the company's stock diagnostic information >

(: congratulations